|
業務類別
|
Biotechnology |
|
業務概覽
|
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which haveinitiated a Phase 3 clinical trial for hyperphagia associated with PWS. |
| 公司地址
| 4370 La Jolla Village Drive, Suite 1050, San Diego, CA, USA, 92122 |
| 電話號碼
| +1 858 225-7696 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.aardvarktherapeutics.com |
| 員工數量
| 40 |
| Dr. Tien-Li Lee, M.D. |
Chief Executive Officer and Chairperson of the Board |
美元 630.79K |
23/03/2026 |
| Dr. Manasi Jaiman, M.D.,M.P.H. |
Chief Medical Officer |
美元 495.96K |
23/03/2026 |
| Dr. Bryan Jones, PhD |
Chief Executive Officer, Ardia Therapeutics, Inc. |
-- |
12/02/2026 |
| Mr. Nelson Sun |
Chief Operating Officer, Chief Financial Officer and Principal Accounting Officer |
美元 432.65K |
12/02/2026 |
| Mr. Derrick C. Li |
Chief Business Officer |
-- |
12/02/2026 |
|
|
| Ms. Susan E. Graf |
Independent Director |
23/03/2026 |
| Dr. Tien-Li Lee, M.D. |
Chief Executive Officer and Chairperson of the Board |
23/03/2026 |
| Dr. Roy D. Baynes, M.D.,PhD |
Independent Director |
23/03/2026 |
| Dr. Jeffrey Chi, PhD |
Lead Independent Director |
23/03/2026 |
| Mr. Victor Tong, Jr |
Independent Director |
23/03/2026 |
|
|
|
|
